Nektar Therapeutics is a clinical-stage biopharmaceutical company. The Company is developing a pipeline of drug candidates that utilizes its PEGylation and advanced polymer conjugate technology platforms, which are designed to enable the development of molecular entities that targets known mechanisms of action. Its pipeline is comprised of drug candidates across a number of therapeutic areas including oncology, pain, anti-infectives and immunology. The Company’s research and development activities involve small molecule drugs, peptides and other biologic drug candidates. The Company’s products are Naloxegol and Naloxegol Fixed-Dose Combination Products, Etirinotecan pegol, BAY41-6551, NKTR-181, NKTR-171, NKTR-192 and NKTR-214.